Literature DB >> 17081752

What is a positive sentinel lymph node in a breast cancer patient? A practical approach.

Gábor Cserni1.   

Abstract

Sentinel lymph node (SN) biopsy has become increasingly used for the staging of breast carcinoma, resulting in the upstaging of this disease, and this has led to concerns with regard to what should be considered a positive SN. Factors influencing the positive staging of an SN include metastasis size, the method used for metastasis detection, the definition of metastasis and the individual pathologist. Until evidence to the contrary emerges, an SN should be considered positive if metastases (nodal involvement >0.2mm in the largest dimension) are detected in it by histology. A target size should be identified, and SNs, as the most likely sites of nodal metastases, should be searched systematically to find (nearly) all of the targeted metastases. The European guidelines for SN assessment have set two such target sizes: as a minimum, all metastases >2mm should be identified, and optimally all micrometastases should also be sought.

Entities:  

Mesh:

Year:  2006        PMID: 17081752     DOI: 10.1016/j.breast.2006.07.004

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  4 in total

Review 1.  Minimal disease in sentinel nodes.

Authors:  Gábor Cserni
Journal:  Pathol Oncol Res       Date:  2008-05-21       Impact factor: 3.201

Review 2.  [Sentinel node biopsy in breast cancer: pathological analysis and interpretation].

Authors:  G Cserni; T Decker
Journal:  Pathologe       Date:  2009-03       Impact factor: 1.011

3.  Internal Mammary Sentinel Node Biopsy in Breast Cancer. Is it Indicated?

Authors:  R Maráz; G Boross; J Pap-Szekeres; M Rajtár; E Ambrózay; G Cserni
Journal:  Pathol Oncol Res       Date:  2013-08-11       Impact factor: 3.201

4.  Evaluation of Tumor Cell Proliferation by Ki-67 Expression and Mitotic Count in Lymph Node Metastases from Breast Cancer.

Authors:  Sura Aziz; Elisabeth Wik; Gøril Knutsvik; Tor Audun Klingen; Ying Chen; Benedicte Davidsen; Hans Aas; Turid Aas; Lars A Akslen
Journal:  PLoS One       Date:  2016-03-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.